With the rise of genomics and proteomics, many clinically significant targets have been discovered in human diseases. However, a relatively small proportion of traditional druggable targets exists, and many targets […]
Covalent drugs refer to those drug molecules that form strong bonds with receptors through the formation of covalent bonds. It all began with aspirin in 1899, gained prominence with ibrutinib in […]
Over the past several decades, direct inhibition of the RAS family of oncogenic proteins has been a significant challenge in the field of drug development. Despite accounting for approximately 30% […]
CK1 functions Protein phosphorylation mediated by protein kinases is essential for the activation and deactivation of many signaling pathways in cells. As a result, abnormal protein kinase activity is frequently […]
Targeted protein degradation (TPD) technology has been developed rapidly in recent years, especially proteolysis targeting chimeras (PROTACs). To date, a large number of degraders have been discovered against more than […]
Introduction of IAP Apoptosis, or programmed death, is a natural cell cycle process designed to eliminate unwanted or damaged cells from the body. In healthy tissues, there is a good […]
Kinases have become an extremely important molecular target for a range of therapeutic targets. The kinase inhibitors are a large group of unique and potent antineoplastic agents which specifically target […]
Proteasome is the main pathway by which misfolded proteins and other proteins are proteolyzed during protein synthesis. It is found in all eukaryotic cells, archaea and some bacteria and is […]
In recent years, immunotherapy aimed at reactivating weakened immune cells in cancer patients has achieved remarkable results, especially immune checkpoint inhibitors, such as programmed cell death protein-1 (PD-1) and cytotoxic […]